Oneview deploys new technology with five-year contract

|

Published 10-JUN-2021 09:38 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

In a development that is likely to propel Oneview Healthcare Plc’s (ASX:ONE) shares even higher, the health-tech group signed a 5-year contract extension with Epworth HealthCare, the largest private health service in Victoria.

Not only is this positive news from a financial perspective in terms of contributing to the company’s long-term visible income stream, as Epworth stands as Oneview’s largest customer in Australia and second largest globally by number of beds, it represents a strong endorsement of the company’s products and services.

The Oneview platform is currently deployed across eight Epworth hospital locations in approximately 1,440 beds.

Epworth will also be expanding the footprint with Oneview in its redevelopment at Epworth Eastern at Box Hill with an additional 63 beds.

Oneview’s shares have increased nearly 500% in the last three months, but with this development providing a significant financial boost and the prospect of further contract flow adding momentum, it wouldn’t be surprising to see the company break above this year’s record closing high of 46 cents struck in mid-April.

Deployment of new technology and increased footprint

As part of the contract renewal, Epworth will be migrating to Oneview’s new Next Generation CXP Enterprise platform and deploying GMS certified healthcare grade 22” Android devices across its diverse care settings.

By way of background, Oneview Healthcare provides digital tools for patients, families, and caregivers to improve the care experience.

By unifying a facility’s systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams.

The company’s products have been embraced on the international stage, partnering with leading healthcare systems in the US, Australia, the Middle East and Asia.

Win-win situation between tech provider and health care client

Discussing the nature of the complementary relationship between Oneview and Epworth, chief executive James Fitter said, “We have enjoyed a very special partnership with Epworth dating back to our initial deployment at Epworth Eastern in Box Hill in January 2015.

"They have been the inspiration for much of our innovation in the Australian market and encouraged us to broaden the platform to include an extensive suite of care team applications which have become an integral part of their care delivery model.”

Highlighting the benefits of Oneview's technologies in the patient care environment, Dr Lachlan Henderson, group chief executive, Epworth HealthCare said, ‘’The agreement will enable Epworth to take digital healthcare into the future.

"The Oneview point-of-care platform has changed the way we deliver care to patients, as well as providing our patients with a unique entertainment and connected experience.

"Our nurses and doctors access our Oneview point of care screens 20,000 times a day, allowing them to update patient information and access medical imaging, radiology and pathology results, at the bedside.

"Patients can also see information about their care and discharge plan.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X